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Abstract
Phyto-oestrogens have been suggested to have a protective effect on hormone-sensitive cancers. However, few studies have investigated
the association between dietary phyto-oestrogens and gynaecological cancers. In the present study, we analysed data from two population-
based case–control studies of ovarian (1366 cases and 1414 controls) and endometrial (1288 cases and 1435 controls) cancers. Dietary
intake information was obtained using a 135-item FFQ, and phyto-oestrogen intake was estimated using published food composition data-
bases. Unconditional logistic regression was used to estimate adjusted OR and 95 % CI. In multivariable analyses, there was a suggestive
pattern of inverse associations between increasing intakes of total phyto-oestrogens, isoflavones and enterolignans and the risk of ovarian
cancer. However, the results only reached statistical significance for the lignan compounds matairesinol and lariciresinol, where the OR
for the highest v. the lowest intake category was 0·72 (95 % CI 0·54, 0·96; P for trend¼0·02) for matairesinol and 0·72 (95 % CI 0·55,
0·96; P for trend¼0·03) for lariciresinol. When the risk of ovarian cancer was assessed by subtype, there was an indication that increasing
intakes of phyto-oestrogens may be associated with a decreased risk of mucinous (cases n 158) ovarian tumours (OR for the highest v. the
lowest intake category: 0·47 (95 % CI 0·24, 0·93); P for trend¼0·04). However, there were no significant associations with other histological
subtypes. In contrast, dietary phyto-oestrogens (total or any subclass) were unrelated to the risk of endometrial cancer cases overall or
by subtype.
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The incidence of hormone-sensitive cancers in Asian countries
such as China and Japan is lower than that in Western
countries, and this has been attributed in part to differences
in dietary factors(1). Asian diets are traditionally more plant
based, lower in fat and higher in fibre and soya products
than Western diets, making them rich in phyto-oestrogens(2).
Phyto-oestrogens are naturally occurring non-steroidal food
compounds that have structural and functional similarities to
17b-oestradiol, a potent oestrogenic steroid, allowing them
to compete with oestradiol by binding to oestrogen receptors.
Their anti-oestrogenic activity has raised the possibility that
these compounds may provide some protection against hor-
mone-sensitive cancers(3,4). Phyto-oestrogens have also been
shown to have antioxidative activity and to influence malig-
nant cell proliferation, differentiation and angiogenesis in
such a way as to make them of interest as potential anti-
cancer compounds(5).
There are three main classes of phyto-oestrogens: isofla-
vones; lignans; coumestans(1). Soya products and chickpeas
are the main sources of isoflavones (genistein, daidzein and
glycitein), while oil seeds, whole grains, legumes, vegetables
and berries are the main food sources of lignans (such as
secoisolariciresinol, matairesinol, lariciresinol and pinoresi-
nol)(6). Coumestrol is the main coumestan consumed by
humans and is present in low concentrations in the diet;
however, it is relatively rich in foods such as mung bean
sprouts and flaxseeds(7). Most of the plant lignans in foods
are converted by bacteria in the upper part of the colon to
the enterolignans enterolactone and enterodiol(8). Equol, a
metabolite of the isoflavone daidzein, is also produced by
intestinal bacteria; however, this process occurs in only
about one-third of the human population(9). Humans also
consume small amounts of pre-formed enterolignans in
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animal products such as milk, as a result of their production
by intestinal bacterial metabolism in animals(10).
Of all the phyto-oestrogens, isoflavones have been the
most widely investigated in relation to gynaecological cancers.
Experimental studies have suggested that genistein and
daidzein can independently modify cytokine production and
reduce ovarian cancer cell proliferation(11,12). Similarly,
genistein appears to protect against oestrogen-induced cell
proliferation in the uterus(13,14). In observational studies,
however, the role of phyto-oestrogens in either ovarian or
endometrial cancer has received relatively little attention,
and the few studies conducted to date have yielded incon-
sistent results. To our knowledge, only two cohort studies
carried out in the USA(15) and Sweden(16) and four case–
control studies conducted in the USA(17,18), Italy(19) and
China(20) have examined the intake of phyto-oestrogens in
relation to ovarian cancer. Overall, the findings have shown
inverse(15,18–20) or null(16,17) associations with the intake of
isoflavones and/or lignans. For endometrial cancer, the only
cohort study to date has reported inverse associations with
the intake of only isoflavones(21). Of three case–control
studies, two US studies(22,23) found no evidence of an associ-
ation with the intake of total phyto-oestrogens, lignans or
isoflavones, while a Chinese study(24) examining soya foods
found an inverse association of borderline significance with
higher intakes of isoflavones.
In the present study, we used data from two large popu-
lation-based case–control studies to evaluate the associations
between dietary intake of phyto-oestrogens, including the
major subclasses and their components, and the risk of
ovarian and endometrial cancers overall and by histological
subtype. To our knowledge, this is the first observational
study of gynaecological cancers to investigate the dietary
intake of enterolignans and the first to examine associa-
tions by histological subtype. We hypothesised that increasing
intakes of total phyto-oestrogens and the major phyto-
oestrogen subclasses would be inversely associated with the
risk of both ovarian and endometrial cancers.
Subjects and methods
Study participants
Study participants were women aged 18–79 years from
two population-based case–control studies conducted in
Australia: the Australian Ovarian Cancer Study (AOCS, diag-
nosis between January 2002 and June 2005) and the Australian
National Endometrial Cancer Study (ANECS, diagnosis
between May 2005 and December 2007). Full details of
study recruitment and data collection methods of the
AOCS(25) and ANECS(26) have been reported previously. In
brief, for the AOCS, 3550 women with suspected ovarian
cancer were identified through major treatment centres and
state-based cancer registries throughout Australia. Of these,
307 died before contact could be made, and a further 498
women were excluded because of language difficulties or
mental incapacity or because they were too sick, could not
be contacted or the physicians refused permission to contact
them. The remaining 2745 with suspected ovarian cancer
were invited to participate in the study, and of these, 2319
(84 %) agreed to participate. After histopathology review,
590 women were excluded because they were found not to
have primary epithelial ovarian cancer, nineteen because
their cancer was first diagnosed before the study period, and
one because she was not an Australian resident at the time
of diagnosis. Of the final 1709 eligible participants, 1612
(94 %) returned the study questionnaire, and the median
time between diagnosis and questionnaire completion was
90 d (3 months). Similarly for the ANECS, 2707 women diag-
nosed with incident endometrial cancer were identified, and
of these, 476 women were excluded because of language dif-
ficulties or mental incapacity, because they were too sick or
could not be contacted, or because physicians refused per-
mission to contact them. The remaining 2231 women were
invited to participate in the study, and of these, 1497 (67 %)
agreed to participate. We excluded thirty-nine women who
did not have primary endometrial cancer or who were diag-
nosed before the study period, leaving a final sample of
1458 eligible women. Of these, 1399 (96 %) completed an
interview where the median time between diagnosis and inter-
view was 167 d (5·5 months).
Population controls for both the AOCS and ANECS were
women aged 18–79 years randomly selected from the
National Electoral Roll (enrolment to vote is compulsory in
Australia) and frequency-matched to cancer cases by age (in
5-year groups) and state of residence. Of the 3442 women
contacted for the AOCS, 1615 (47 %) consented to participate;
however, women with a history of ovarian cancer or a bilateral
oophorectomy were excluded from the AOCS analyses, leav-
ing 1509 women in the control group. Population controls
for the ANECS were sampled using methods identical to
those used in the AOCS, with 740 women (participation rate
53 %) being recruited between 2005 and 2007. Informed
written consent was obtained from all the participants, and
both studies were approved by the Human Research Ethics
Committees at the Queensland Institute of Medical Research
and all participating institutions.
To increase the power of endometrial cancer analyses, we
also included a random sample of 799 AOCS control women
(after exclusion of women who reported a prior hysterectomy
or endometrial cancer), selected to match the state of resi-
dence and age distribution of the endometrial cancer case
group, giving a total of 1539 control women. The two subsets
of controls were very similar with regard to menopausal
status, parity, oral contraceptive use, hormone replacement
therapy (HRT) use, smoking, BMI and diabetes (all P.0·1).
There were also no significant differences between the two
groups of controls with respect to the intake of phyto-
oestrogens overall or any subclass except lignans, where the
median intake for the endometrial cancer study controls
was approximately 13 % higher (P,0·001) than that for the
subset of ovarian cancer study controls. Therefore, we
conducted sensitivity analyses restricted to the original
ANECS participants to assess whether the inclusion of
additional controls had affected the final results.
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Dietary intake assessment
For both the studies, dietary intake information was obtained
using a 135-item semi-quantitative FFQ based on the instrument
developed by Willett et al.(27), but modified and validated for
use in Australia(28–30). The questionnaire was designed to
reflect the typical dietary intakes of Australians and has been
found to be reproducible among Australian adult popu-
lations(31). For each food, a commonly used portion size was
specified, and women were asked as to how often they had
consumed each food item in the previous year (controls) or in
the year before their diagnosis (cases). There were nine
response options ranging from ‘never’ to ‘four or more times
per day’. Of particular interest for the estimation of isoflavone
intake, the soya food group included the following food
items: soya milk; low-fat soya milk; soyabeans; soya-based
meat substitutes; soyabean and linseed bread. Women who
reported that they had changed their diet in the last year or
two were asked to report their usual diet before the change.
The participants also provided detailed information on the
use of dietary supplements. Daily intake of energy (kJ/d)
was estimated using the 2007 electronic release version of the
Australian food composition table NUTTAB 2006(32).
Because the Australian food composition table lacked infor-
mation on the phyto-oestrogen content of foods, we used a
database developed in the UK by the European Investigation
into Cancer and Nutrition-Norfolk(33,34) to estimate the dietary
intake of individual isoflavones (daidzein, genistein, glycitein,
biochanin A and formononetin), enterolignans (enterolactone,
enterodiol and equol), and coumestrol and the lignans
matairesinol and secoisolariciresinol from food sources. The
database used is based on direct analyses of foodstuffs using
validated methods(34). Development of the database included
an investigation of the variability of foods from different
sources(35). We compared published data on the isoflavone
content of bread, soyabeans and soya products in Australia
with those in the UK database and found values to be com-
parable(6). Furthermore, as in the UK(36), in Australia, soya is
used in the production of bread to help improve bread quality.
Dietary intake of the lignans lariciresinol and pinoresinol(7)
and intake of phyto-oestrogens from supplements were esti-
mated using a published Canadian database(37). Although
equol is a metabolite of daidzein and not a lignan, we included
equol in the estimation of the intake of the subclass of enter-
olignans because it is produced by intestinal microflora, as are
enterodiol and enterolactone(6,33). As the use of supplements
containing phyto-oestrogens was very low in the populations
of the present study (8–11 %), the results were almost identical
whether the intake from only food sources or combined
intake from foods and supplements was examined. Therefore,
we considered the intake of phyto-oestrogens from only food
sources in all the subsequent analyses.
Statistical analyses
Of the 1612 cases and 1509 controls who completed the main
questionnaire in the ovarian cancer study, we further excluded
155 cases and forty-eight controls who did not return the FFQ,
twenty-eight cases and four controls with more than 10 %
of FFQ items missing, and sixty-three cases and forty-three
controls whose estimated daily energy intake was deemed
implausible (,2940 kJ or .16 800 kJ), leaving 1366 cases
and 1414 controls for the final analysis. Of the 1399 cases
and 1539 controls who completed an interview in the endo-
metrial cancer study, we further excluded thirty-three cases
and forty-two controls who did not return the FFQ, fifteen
cases and sixteen controls with more than 10 % of FFQ items
missing, and sixty-three cases and forty-six controls with
extreme energy intake, leaving 1288 cases and 1435 controls
for the final analysis.
Dietary phyto-oestrogen intake was adjusted for total
energy intake using the residual method as described by
Willett et al.(38). Because the distributions of dietary intakes of
phyto-oestrogens were skewed towards higher values, four
categories of phyto-oestrogen intakes were created, which
allowed us to better contrast the highest dietary intake (top
15 %) with the lowest (bottom 20 %, used as the reference
category). OR and 95 % CI were estimated using unconditional
multivariable logistic regression. To test for linear trend
across the intake levels of phyto-oestrogens, we modelled the
median value in each category as a continuous variable.
For both the studies, multivariable analyses were adjusted
for factors strongly associated with phyto-oestrogen intake
and/or cancer risk including age (in years), parity (0, 1–2
or $3), oral contraceptive use (never, ,60 months or
$60 months), HRT use (never, ,3 months or $3 months),
BMI (,25, 25–29·9 or $30 kg/m2), alcohol consumption
(number of standard drinks per week), smoking status
(current, ex-smoker or non-smoker) and energy intake
(log transformed). For the ovarian cancer study, we also
adjusted for education (high school, technical college or
university), hysterectomy (yes/no) and menopausal status
(pre/peri-menopausal or postmenopausal). Additional covari-
ates for the endometrial cancer study included age at menarche
(#12, 12–14 or .14 years) and type 2 diabetes (yes/no).
Multiplicative interaction terms were entered into the
logistic regression model to test for effect modification by
menopausal status and HRT use (pre/peri-menopausal or
postmenopausal and no HRT use or postmenopausal with
HRT use) for both cancer studies. For endometrial cancer,
we also tested for the possibility of effect modification by
obesity (BMI ,30 v. $30 kg/m2). These variables were
selected a priori based on our knowledge of the relationship
between these factors and oestrogen levels and the import-
ance of BMI as a strong risk factor for endometrial cancer.
Analyses were carried out for all the tumour subtypes com-
bined and then separately by histological subtype. For ovarian
cancer, we examined the endometrioid (cases n 113), muci-
nous (cases n 158), clear-cell (cases n 69), invasive serous
(cases n 693) and borderline serous (cases n 120) subtypes
separately, and for endometrial cancer, we defined type I as
low-grade endometrioid tumours (cases n 993) and type II
(cases n 295) as all other epithelial subtypes (including
serous and clear-cell, high-grade endometrioid and carcino-
sarcoma subtypes). All the statistical analyses were carried
out using SAS version 9.2 (SAS Institute, Inc.).
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Results
The characteristics of the study participants are given in Table 1.
Women with ovarian cancer were older and more likely to be
postmenopausal, to have had a hysterectomy and to be current
smokers compared with the control women. Endometrial
cancer cases were more likely to have never smoked, to be
obese and to have type 2 diabetes compared with control
women. For both cancers, cases were more likely than
controls tobenulliparous, tohaveneverusedoral contraceptives
or HRT, and to abstain from alcohol consumption. Almost all
the participants (96%) reported Caucasian ethnicity.
Among control women, phyto-oestrogen intake was equal
to 1·27 mg/d in the ovarian cancer study and 1·31 mg/d in
the endometrial cancer study, of which 0·59/0·63 mg were
derived from isoflavones, 0·63/0·66 mg from lignans, 0·02/
0·02 mg from enterolignans and 0·01/0·01 mg from coumestrol.
In the ovarian cancer study, median total intake of phyto-
oestrogens and lignans from food sources was significantly
higher in controls than in cases (Table 2). Endometrial
Table 1. Characteristics of ovarian and endometrial cancer cases and controls
(Mean values and standard deviations; number of cases and controls and percentages)
Ovarian cancer Endometrial cancer
Cases
(n 1366)*
Controls
(n 1414)*
Cases
(n 1288)*
Controls
(n 1435)*
n % n % P n % n % P
Age (years)
Mean 57·6 56·3 61·3 60·8
SD 12·0 12·5 0·03† 9·4 9·8 0·18†
Education
High school 722 52·9 695 49·2 665 51·6 702 48·9
Technical college 445 32·6 516 36·5 425 33·0 529 36·9
University 199 14·6 203 14·4 0·08 198 15·4 204 14·2 0·11
Age at menarche
#12 years 559 40·9 531 37·6 293 22·9 221 15·7
12–14 years 375 27·5 398 28·1 836 65·4 972 69·1
. 14 years 432 31·6 485 34·3 0·16 149 11·7 214 15·2 0·23
Parity
0 267 19·6 166 11·7 229 17·8 124 8·6
1 or 2 558 40·9 608 43·0 502 39·0 619 43·1
3 þ 539 39·5 640 45·3 ,0·001‡ 557 43·2 692 48·2 ,0·001‡
OC use
Never 431 31·7 295 20·9 414 32·6 291 20·5
, 60 months 364 26·8 348 24·7 453 35·7 381 26·9
$ 60 months 563 41·5 768 54·4 ,0·001‡ 404 31·8 746 52·6 ,0·001‡
Menopausal status
Pre/peri-menopausal 394 28·8 483 34·2 256 19·9 274 19·1
Postmenopausal 972 71·2 931 65·8 0·003 1032 80·1 1161 80·9 0·61
HRT use
Never or ,3 months 474 49·0 414 44·5 925 72·2 902 63·2
$ 3 months 494 51·0 517 55·5 0·05 357 27·8 526 36·8 ,0·001
Hysterectomy
No 932 68·3 1129 79·8 NA
Yes 432 31·7 285 20·2 ,0·001‡
BMI
, 25 kg/m2 560 42·4 642 46·0 325 26·0 650 46·1
25–29·9 kg/m2 450 34·0 429 30·7 321 25·7 460 32·6
$ 30 kg/m2 312 23·6 325 23·3 0·11‡ 603 48·2 300 21·3 ,0·001‡
Type 2 diabetes
No 1283 93·9 1338 95·0 1121 87·0 1360 95·0
Yes 83 6·1 71 5·0 0·23 167 13·0 72 5·0 ,0·001
Alcohol consumption§
0 309 22·7 231 16·3 430 33·4 249 17·4
, 1 169 12·4 181 12·8 333 25·9 303 21·1
1–6 590 43·3 653 46·2 315 24·5 503 35·1
7–20 242 17·8 314 22·2 162 12·6 303 21·1
$ 21 53 3·9 34 2·4 ,0·001‡ 48 3·7 77 5·4 ,0·001‡
Smoking status
Current 221 16·2 160 11·3 120 9·3 132 9·2
Ex-smoker 370 27·1 416 29·4 332 25·8 442 30·8
Never 775 56·7 837 59·2 0·001‡ 836 64·9 860 60·0 0·01‡
OC, oral contraceptive; HRT, hormone replacement therapy; NA, not applicable.
* Numbers may not sum to total due to missing data.
† t test.
‡ x 2 test for trend.
§ Standard drinks/week (1 standard drink ¼ 10 g alcohol).
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cancer cases and controls did not differ significantly according
to median total intake of phyto-oestrogens or any phyto-
oestrogen subclass except for the intake of coumestrol,
which, although low, was significantly higher among controls
(Table 2).
Risk estimates for total intake of phyto-oestrogens, major
subclasses and individual compounds are given in Table 3.
In crude analyses, there was an indication of inverse associ-
ations with higher intakes of phyto-oestrogens, isoflavones
and lignans; however, after adjustment, the only statistically
significant results were obtained for the lignan compounds
matairesinol and lariciresinol (Table 3). The adjusted OR for
the highest v. the lowest intake category was 0·72 (95 % CI
0·54, 0·96; P for trend¼0·02) for matairesinol and 0·72 (95 %
CI 0·55, 0·96; P for trend ¼ 0·03) for lariciresinol.
In contrast, there was no clear pattern of endometrial cancer
risk with increasing intakes of total phyto-oestrogens or any
of the subclasses. However, a borderline significant positive
association was observed for matairesinol, where the adjusted
OR for the highest v. the lowest intake category was 1·33 (95 %
CI 0·99, 1·79; P for trend¼0·03). As we had previously observed
a significant difference between the AOCS and ANECS controls
included in the endometrial cancer analyses with respect to the
intake of lignans, we conducted sensitivity analyses including
only the ANECS controls (n 626) recruited at the same time as
the endometrial cancer cases. Overall, the results were similar
to those observed from the larger study sample, confirming
the null results for phyto-oestrogens, lignans, isoflavones and
coumestrol. Of note, there was no longer any association
between matairesinol intake and endometrial cancer risk (OR
0·91, 95 % CI 0·63, 1·33; P for trend¼0·71).
In the ovarian cancer study, we observed significant
interactions between the combined menopausal status–HRT
use (never or ,3 months v. $3 months) variable and total
intake of phyto-oestrogens (P for interaction¼0·03) and enter-
olignans (P for interaction¼0·03). The interaction test for
isoflavones approached significance (P for interaction¼0·07).
There was a significant inverse trend for phyto-oestrogens
(OR for the highest v. the lowest intake category: 0·52 (95 %
CI 0·31, 0·88); P for trend¼0·002) and for isoflavones (OR
0·50, 95 % CI 0·30, 0·84; P for trend¼0·003) only among post-
menopausal women who had never used HRT, whereas the
intake of enterolignans was inversely associated with ovarian
cancer risk among postmenopausal women who had used
HRT (OR 0·47, 95 % CI 0·29, 0·76; P for trend¼0·01). In
the endometrial cancer study, no significant effect modifi-
cation was observed between the combined menopausal
status–HRT use variable or obesity and total intake of
phyto-oestrogens or any subclass (data not shown).
We also investigated the phyto-oestrogen–cancer associ-
ations with the different histological subtypes of ovarian and
endometrial cancers (data not shown). For ovarian cancer,
we found an inverse association between total intake of
phyto-oestrogens and the risk of mucinous ovarian tumours
(OR for the highest v. the lowest intake category: 0·47 (95 %
CI 0·24, 0·93); P for trend¼0·04) with borderline significant
associations for isoflavones (OR 0·55, 95 % CI 0·28, 1·07; P for
trend¼0·06) and lignans (OR 0·56, 95 % CI 0·29, 1·07; P for
trend¼0·07). However, there were no significant associations
with non-mucinous tumours, separately or combined. For
endometrial cancer, the results did not differ by subtype
(type I or type II).
Table 2. Energy and energy-adjusted* phyto-oestrogen intakes from foods in ovarian and endometrial cancer cases and controls
(Median values and interquartile ranges (IQR))
Ovarian cancer Endometrial cancer
Cases (n 1366) Controls (n 1414) Cases (n 1288) Controls (n 1435)
Median IQR Median IQR P† Median IQR Median IQR P†
Total energy (kJ) 8740 3647 8699 3466 0·87 8883 3423 8782 3335 0·53
Phyto-oestrogens (mg/d)‡ 1207 1458 1270 1744 0·04 1297 1694 1312 1850 0·33
Isoflavones 537 1246 586 1523 0·10 615 1441 631 1657 0·67
Daidzein 175 392 188 446 0·11 199 444 204 498 0·70
Genistein 299 795 336 969 0·11 348 925 351 1059 0·67
Glycitein 38 69 41 90 0·06 42 66 42 84 0·40
Biochanin A 19·6 9·6 19·9 9·2 0·14 19·8 8·7 20·1 9·2 0·36
Formononetin 3·1 1·6 3·2 1·6 0·02 3·2 1·5 3·3 1·6 0·18
Lignans 609 329 630 308 0·02 657 342 659 328 0·15
Secoisolariciresinol 400 241 419 227 0·03 430 251 437 234 0·13
Matairesinol 55 34 57 38 0·01 60 46 61 45 0·50
Pinoresinol 53 39 52 37 0·64 51 35 54 34 0·01
Lariciresinol 77 44 81 44 0·01 80 42 81 42 0·17
Enterolignans 20·5 15·6 20·4 15·1 0·80 20·8 14·8 20·6 14·5 0·99
Enterolactone 15 11·9 15 11·7 0·76 15·2 10·9 15 10·9 0·99
Enterodiol 0·03 0·04 0·04 0·05 0·50 0·04 0·05 0·05 0·05 0·98
Equol 5·4 3·7 5·4 3·9 0·99 5·4 3·9 5·4 3·8 0·14
Coumestrol 7·6 6·9 8 6·4 0·06 7·3 6 7·6 6·4 0·01
* Energy adjusted using the residual method.
†P value from the Wilcoxon two-sample test.
‡ Total phyto-oestrogen intake¼sum of intakes of isoflavones, lignans, enterolignans and coumestrol.
A. S. Neill et al.1434
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://doi.org/10.1017/S0007114513003899
Downloaded from https:/www.cambridge.org/core. UQ Library, on 03 Feb 2017 at 04:09:31, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
Table 3. Adjusted OR for the risk of ovarian and endometrial cancers associated with phyto-oestrogen intake from foods
(Adjusted odds ratios and 95 % confidence intervals)
Ovarian cancer Endometrial cancer
Phyto-oestrogens (mg/d)
Cases
(n 1366)
Controls
(n 1414) OR* 95 % CI
P for
trend
Cases
(n 1288)
Controls
(n 1435) OR† 95 % CI
P for
trend
Total phyto-oestrogens
,900 331 337 1·00 (reference) 258 290 1·00 (reference)
900–1400 439 441 1·05 0·85, 1·30 446 484 1·11 0·87, 1·41
1401–5000 359 398 0·93 0·74, 1·16 416 446 1·24 0·97, 1·59
. 5000 175 215 0·86 0·66, 1·12 0·17 168 215 1·14 0·85, 1·53 0·19
Isoflavones
, 280 306 315 1·00 (reference) 242 274 1·00 (reference)
280–700 648 456 1·10 0·89, 1·36 474 505 1·02 0·80, 1·29
701–4000 356 403 0·94 0·75, 1·17 404 438 1·14 0·89, 1·46
. 4000 174 217 0·87 0·66, 1·13 0·13 168 218 1·06 0·79, 1·43 0·40
Daidzein
, 90 332 340 1·00 (reference) 269 302 1·00 (reference)
90–230 447 444 1·04 0·85, 1·29 439 480 0·98 0·78, 1·24
231–1200 351 397 0·92 0·74, 1·15 408 440 1·10 0·87, 1·40
. 1200 174 210 0·87 0·67, 1·14 0·23 172 213 1·07 0·80, 1·43 0·38
Genistein
, 150 306 322 1·00 (reference) 250 283 1·00 (reference)
150–400 463 453 1·11 0·90, 1·37 460 495 1·00 0·79, 1·27
401–2700 365 407 0·97 0·78, 1·21 413 451 1·12 0·88, 1·43
. 2700 170 209 0·89 0·68, 1·17 0·19 165 206 1·10 0·82, 1·48 0·31
Glycitein
, 20 246 235 1·00 (reference) 192 201 1
20–50 544 574 0·95 0·76, 1·19 579 615 1·03 0·79, 1·33
50–250 347 376 0·91 0·71, 1·16 368 412 1·06 0·81, 1·40
. 250 167 206 0·81 0·61, 1·08 0·17 149 207 0·93 0·67, 1·29 0·82
Biochanin A
, 15 246 245 1 243 256 1·00 (reference)
15–20 419 458 0·90 0·72, 1·13 419 452 1·08 0·84, 1·38
21–30 439 482 0·90 0·72, 1·13 448 516 0·96 0·75, 1·22
. 30 182 206 0·85 0·64, 1·12 0·32 178 211 1·09 0·81, 1·47 0·98
Formononetin
, 2·5 277 232 1 224 225 1·00 (reference)
2·5–3·5 499 588 0·71 0·57, 0·89 531 606 0·90 0·70, 1·15
3·6–5·0 330 331 0·83 0·65, 1·06 337 351 1·12 0·85, 1·46
. 5·0 198 240 0·69 0·52, 0·91 0·12 196 253 0·97 0·72, 1·31 0·50
Lignans
, 450 290 255 1·00 (reference) 241 219 1·00 (reference)
450–700 538 596 0·82 0·66, 1·02 499 582 0·98 0·76, 1·25
701–4000 323 375 0·78 0·61, 0·99 396 440 1·09 0·84, 1·42
. 4000 153 165 0·83 0·62, 1·11 0·22 152 194 1·07 0·78, 1·47 0·40
Secoisolariciresinol
, 290 287 256 1 243 221 1·00 (reference)
290–450 515 566 0·83 0·67, 1·03 449 533 0·95 0·74, 1·23
451–650 316 369 0·79 0·62, 1·01 383 437 1·07 0·82, 1·39
. 650 186 200 0·86 0·65, 1·13 0·35 213 244 1·21 0·90, 1·63 0·10
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Table 3. Continued
Ovarian cancer Endometrial cancer
Phyto-oestrogens (mg/d)
Cases
(n 1366)
Controls
(n 1414) OR* 95 % CI
P for
trend
Cases
(n 1288)
Controls
(n 1435) OR† 95 % CI
P for
trend
Matairesinol
,40 302 285 1 240 239 1
40–60 463 470 0·97 0·78, 1·21 397 451 1·14 0·88, 1·47
61–100 378 432 0·92 0·73, 1·15 404 467 1·28 0·98, 1·66
. 100 161 204 0·72 0·54, 0·96 0·02 247 278 1·33 0·99, 1·79 0·03
Pinoresinol
, 30 243 241 1·00 (reference) 242 196 1·00 (reference)
30–55 470 514 0·91 0·72, 1·14 480 556 0·79 0·61, 1·02
56–80 337 385 0·85 0·67, 1·09 355 429 0·74 0·57, 0·97
. 80 254 251 0·98 0·75, 1·28 0·91 211 254 0·76 0·56, 1·03 0·07
Lariciresinol
, 55 276 238 1·00 (reference) 248 244 1·00 (reference)
55–85 484 529 0·80 0·64, 1·00 480 540 1·06 0·83, 1·35
85–120 370 421 0·77 0·61, 0·97 405 460 1·07 0·83, 1·38
. 120 174 203 0·72 0·55, 0·96 0·03 155 191 0·95 0·69, 1·29 0·85
Enterolignans
, 12 249 265 1·00 (reference) 247 274 1
12–22 482 492 1·05 0·84, 1·32 457 518 1·04 0·83, 1·29
23–35 398 431 1·03 0·82, 1·29 420 452 1·14 0·89, 1·45
. 35 175 203 0·88 0·67, 1·16 0·37 164 191 0·89 0·66, 1·22 0·95
Coumestrol
, 5 296 273 1·00 (reference) 310 295 1
5–10 571 602 0·89 0·73, 1·10 595 644 1·04 0·83, 1·29
10–15 233 292 0·76 0·59, 0·97 211 279 0·86 0·66, 1·13
. 15 204 224 0·86 0·66, 1·12 0·31 172 217 0·89 0·67, 1·19 0·20
* OR and 95 % CI adjusted for age, energy intake (log transformed), hysterectomy, menopausal status, education, parity, oral contraceptive use, hormone replacement therapy use, BMI, alcohol consumption and smoking status.
† OR and 95 % CI adjusted for age, energy intake (log transformed), age at menarche, parity, oral contraceptive use, hormone replacement therapy use, BMI, type 2 diabetes, alcohol consumption and smoking status.
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Discussion
The findings of the present study suggest a possible inverse
association between consumption of phyto-oestrogens and
the risk of ovarian cancer. However, most results did not
reach statistical significance at intake levels reported in the
Australian study population considered in the present study,
for whom the median intake of phyto-oestrogens was
1·27 mg/d. Furthermore, when we examined associations by
histological subtype, the inverse results appeared to be largely
driven by mucinous ovarian tumours, and there was little or
no association for other subtypes. We found no evidence of
an association between dietary intake of phyto-oestrogens or
any of the main classes and the risk of endometrial cancer
overall or by histological subtype.
Ovarian cancer
Previous studies in Western populations have found null(16,17)
or inverse(15,19–21) associations between increasing intakes of
isoflavones and the risk of ovarian cancer. Of two other
case–control studies, one carried out in Italy has reported sig-
nificant inverse associations with the highest quintile of intake
of isoflavones(19), while a US population-based study(17) has
suggested that isoflavones and their components may
decrease ovarian cancer risk, although similar to those of the
present study, the results did not reach statistical significance
for isoflavones, daidzein, genistein or glycitein. Among other
Western populations, a recent Swedish cohort(16) study has
found no association between phyto-oestrogen intake and
overall ovarian cancer risk. However, in that study, the
mean daily intake of total isoflavones (including genistein,
daidzein, formononetin, biochanin A and equol) was only
0·07 mg/d.
In contrast, a case–control study conducted in China(20) has
reported that the highest intakes of total isoflavones and the
compounds daidzein, genistein and glycitein are each associ-
ated with about half the risk of ovarian cancer compared with
the lowest intakes. However, soya is widely consumed in
China, unlike the Western diet in which lignans are the
predominant phyto-oestrogens. The mean daily intake of iso-
flavones in the Chinese study controls was 24·7 mg/d, much
higher than the mean 2·7 mg/d consumed by the population
controls in the present study, in which the majority of partici-
pants were classified as being of Caucasian ethnicity. Since
then, a cohort study conducted in the USA has reported that
compared with the relative risk associated with the consump-
tion of less than 1 mg isoflavones/d, that associated with the
consumption of more than 3 mg/d is 0·56 in women (95 %
CI 0·33, 0·96; P for trend¼0·04)(15).
With respect to lignans, we found that increasing intakes of
the lignans lariciresinol and matairesinol were associated with
a reduced risk of ovarian cancer, despite their relatively small
contribution to overall lignan intake. Similarly, a US popu-
lation-based case–control study has found a reduced risk for
women with the highest quintile of intake of total lignans
(combined secoisolariciresinol and matairesinol) compared
with those with the lowest intake(18). In contrast, both the
Swedish cohort study(16) and another US population-based
case–control study(17) have found no association between
intake of total lignans and the risk of ovarian cancer.
It is not clear why associations might be stronger for laricir-
esinol and matairesinol than for other lignans; however, Adler-
creutz(8) has suggested that the oestradiol-binding nuclear
type II binding sites may mediate the anti-cancer action of lig-
nans and that, of the lignans tested, matairesinol is the most
effective at binding to these sites(39). Others have reported
decreased risks of breast cancer associated with higher intakes
of matairesinol, but not with those of secoisolariciresinol or
total lignans(40).
In the ovarian cancer study, we observed significant inter-
actions between the combined menopausal status–HRT use
variable and total intake of phyto-oestrogens and entero-
lignans. There was a significant inverse trend for total intake
of phyto-oestrogens and for the intake of only isoflavones
among postmenopausal women who had never used HRT,
whereas the intake of enterolignans was inversely associated
with ovarian cancer risk only among postmenopausal
women who had used HRT. Due to the anti-oestrogenic
activity attributable to phyto-oestrogens, we hypothesised
that inverse associations might be stronger among women
who had the highest levels of oestrogen, i.e. pre-menopausal
women and postmenopausal women taking HRT. However,
this was not the case; the inconsistent results that we observed
may have been due to our inability to differentiate between
different types of HRT or they may be chance findings due
to the multiple comparisons made.
In the present study, we also examined associations by his-
tological subtype of ovarian cancer and found an indication of
an inverse association between total intake of phyto-
oestrogens and the risk of mucinous ovarian tumours, but
no significant associations with non-mucinous subtypes,
suggesting different aetiologies. Previous epidemiological
studies have reported differences in associations with both
reproductive and non-reproductive exposures for mucinous v.
non-mucinous cancers(41–46). Future epidemiological studies
should consider the possibility that the effects of phyto-
oestrogen intake may also differ by ovarian cancer subtypes.
Endometrial cancer
Contrary to our a priori hypothesis, we found no evidence of
an association between total dietary phyto-oestrogens or any
phyto-oestrogen subclass and endometrial cancer risk.
Similarly, findings from two US population-based case–
control studies(22,23) did not support a protective effect of
dietary phyto-oestrogens on the risk of endometrial cancer.
Although Bandera et al.(22) reported a suggestion of an inverse
association with the intake of total isoflavones in women with
BMI , 25 kg/m2, but no effect modification by HRT use, we
found no evidence of effect modification by BMI or HRT use.
To our knowledge, the Multiethnic Cohort Study(21) is the
only study to have reported a significantly reduced risk of
endometrial cancer with higher intakes of total isoflavones.
Notably, the association was found only at consumption
levels approximately eleven times higher than the estimated
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US average of 1·0 mg/d(47). In contrast, an Asian case–control
study has reported limited evidence of an inverse association
with isoflavones, even at intake levels .63 mg/d (highest
quartile: OR 0·77, 95 % CI 0·56, 1·05; P for trend¼0·05)(24).
The mean intake of isoflavones in our Australian population
controls was only 2·6 mg/d (median 0·6 mg/d). It is possible
that the strong effects of unopposed oestrogen on the risk
of endometrial cancer may be overriding any effect produced
by the relatively low intake of dietary phyto-oestrogens in our
Western population. Furthermore, our null results for dietary
lignans and enterolignans are corroborated by the lack of an
association found in the only study to date that has investi-
gated circulating enterolactone levels as a biomarker for
plant lignan intake(48).
Conclusions
Several mechanisms have been postulated to explain the
potential protective effects of phyto-oestrogens on hormone-
related cancers. Phyto-oestrogens have been shown to exert
effects on sex hormone metabolism, as well as possess several
non-hormonal cancer-protective properties that influence
antioxidative activity, intracellular enzyme activity, protein syn-
thesis, and malignant cell proliferation, differentiation and
angiogenesis(5). Specifically, isoflavones (found in soya-based
foods) can bind to oestrogen receptors, although weakly
compared with endogenous oestrogen, and have a number of
other mechanisms of action including antioxidant activity, inhi-
bition of tyrosine kinases (which influence unregulated cell
growth) and inhibition of metastasis(49). The lack of an associ-
ation between intake of isoflavones and the risk of endometrial
cancer, which is strongly associated with oestrogen exposure,
may suggest that any association with ovarian cancer may be
mediated more by the non-oestrogenic effects of isoflavones.
Both lignans and enterolignans increase plasma sex hormone-
binding globulin levels, thus reducing the levels of free
biologically active sex hormones(8). In addition, plant-based
diets contain more fibre, which reduces intestinal reabsorption
of oestrogen(8). Overall, there is limited but suggestive evidence
that the intake of non-starchy vegetables may decrease the
risk of both ovarian and endometrial cancers, although the
exact mechanisms of protection remain mostly unknown
and any protective effect may result from a combination of
influences on several pathways involved in carcinogenesis(50).
The strengths of the present study include samples of large
sizes obtained from two national population-based case–
control studies, the use of a comprehensive and reproducible
FFQ(31) and the use of comprehensive food composition data-
bases to estimate phyto-oestrogen intake(7,51). Overall, the
intake of phyto-oestrogens and subclasses in the present
study was comparable to other reports based on Western
populations(17,18,22,47,51). However, selection bias is a
particular problem in case–control studies, and we
acknowledge that the response rate among controls in the
two studies investigated was low at around 50 %. Previous
comparisons of the AOCS controls with the 2004 Australian
National Health Survey participants(52) have shown that distri-
butions of key variables (education level, parity, BMI and
smoking status) are comparable with national data(53).
Furthermore, the two studies were conducted in comparable
populations of Australian women at similar time periods
(2002–5 and 2005–7) and using identical methods, yet we
found a suggestive overall pattern of reduction in the risk of
ovarian cancer with increasing intakes of phyto-oestrogens,
but no association for endometrial cancer. It seems reasonable
to assume that any selection bias would be similar in the two
studies and so could not produce differing results.
As is common to all case–control studies, there may have
been recall bias associated with reporting of dietary intake
data and other factors are difficult to quantify. We acknowledge
that there is a high variability in the isoflavone content of
different soya products(54). Although the FFQ that was used
was designed to include the most commonly consumed soya-
bean food items in the Australian diet, it was not designed to
specifically investigate the intake of phyto-oestrogens or their
respective subclasses. The absorption of plant lignans and sub-
sequent bioconversion to enterolignans vary greatly between
individuals(10). In addition to dietary intakes, many other factors
such as smoking and obesity affect the levels of circulating
lignans(8), although we were able to adjust for smoking and
obesity in the present study. Comparable to that observed in
other studies in Western populations, we observed much
lower intakes of phyto-oestrogens than those typically observed
in Asian populations, and these may have been insufficient to
observe an association, if in fact one exists. Similarly to other
observational studies(15–24), we measured dietary intake using
a validated FFQ and restricted information to recent dietary
history (previous 1–2 years). This may have attenuated our
findings if the participants had changed their diets, as it has
been suggested that a lifetime exposure to phyto-oestrogens
may be needed to gain full health benefits(8,55).
In summary, the results of these large population-based
case–control studies suggest that phyto-oestrogens have no
major protective role in either ovarian or endometrial cancer
at the levels typically consumed by Western populations.
However, the results suggest a possible inverse association
between higher intakes of dietary phyto-oestrogens and the
risk of ovarian cancer. Studies examining the circulating
levels of phyto-oestrogens and the risk of ovarian cancer over-
all and by histological subtype may be helpful in exploring
this association further.
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